ARCHIVES

Iressa Authorization In Europe Clarifies Differences Between U.S., E.U. Standards

This article is from The Cancer Letter archive.

Vol. 35 No. 30 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention

January 10, 1997

Cyclamate Committee Finds No Proof Of Carcinogenicity

January 23, 1976

FEBT, For Pain Control, Shows Positive Results In Phase III

May 26, 2006

Technology Isolates and Recovers Circulating Liver Tumor Cells

April 27, 2012

DCT Board Approves Three New BRMP RFAs For Immunologic Research, $1.5 Million A Year

February 27, 1987

Bristol-Myers, Karolinska In Collaboration For Studies.

March 31, 2000